NCT05829460 - Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2032

Conditions

Endometrial Hyperplasia

Interventions

DRUG

Semaglutide

This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.

DRUG

Placebo

This medication is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm; injection site should be rotated when using the same body region.

DRUG

LNG-IUD (Progestin)

Released via the levonorgestrel-releasing IUD.

BEHAVIORAL

Telemedicine behavioral weight program

Optional to attend.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis